Accurate epilepsy classification determines treatment efficacy, prognostic counseling, and surgical evaluation. When the International League Against Epilepsy released its updated operational framework in 2017, the clinical community gained a multi-tiered diagnostic model that moves beyond outdated EEG-centric terminology. Grasping this framework requires looking at how seizures are categorized by onset, organized by type, and tied to distinct etiological factors.
The Three-Level Diagnostic Framework
The 2017 ILAE operational classification structures diagnosis across three distinct levels. Clinicians don't just assign a single label; they build a clinical profile from the ground up as diagnostic certainty increases.
- Level 1: Seizure Type. The initial step identifies whether the seizure onset is focal, generalized, or unknown. This level relies heavily on semiology when specialized testing isn't immediately available.
- Level 2: Epilepsy Type. Once seizure types are established, clinicians determine the overarching epilepsy category: focal, generalized, combined generalized and focal, or unknown.
- Level 3: Epilepsy Syndrome. The final diagnostic tier integrates electroclinical findings, age of onset, EEG patterns, and triggers to identify specific syndromes like West syndrome or Dravet syndrome.
For example, a patient might present with focal aware seizures (Level 1), be diagnosed with focal epilepsy (Level 2), and ultimately receive a classification of temporal lobe epilepsy with hippocampal sclerosis (Level 3).
Level 1: Determining Seizure Onset
Classifying a seizure starts with identifying where in the brain the network activity begins. The 2017 guidelines updated these categories to reflect modern neuroimaging and electrophysiological insights. Similar insight on the subject has been published by BBC.
Focal Onset Seizures
Focal seizures originate within networks limited to one cerebral hemisphere. They can be discretely localized or more widely distributed. The description further details whether awareness is retained or impaired during the event. Motor versus non-motor onset characteristics are then noted, such as automatisms,atonic drops, or sensory disturbances.
Generalized Onset Seizures
Generalized seizures originate at some point within, and rapidly engage, bilaterally distributed brain networks. These include tonic-clonic, absence, myoclonic, clonic, and tonic seizures. Retaining precise observational notes on the very first sign of motor involvement prevents misdiagnosing a focal seizure that rapidly bilateralizes.
Unknown Onset Seizures
When healthcare providers lack sufficient information to classify a seizure as focal or generalized—often due to unwitnessed nocturnal events or obscured clinical signs—it's categorized as unknown onset. This serves as a temporary placeholder until monitoring or ambulatory testing provides clarity.
Level 2 and Level 3: Types and Syndromes
Moving beyond the individual seizure event, Level 2 establishes the overarching epilepsy type. The 2017 revision introduced the combined generalized and focal category to accommodate patients who clearly manifest both seizure types, such as those with certain genetic encephalopathies.
Level 3 incorporates etiology across all diagnostic tiers. The ILAE defines six distinct etiological categories that must be considered concurrently with seizure and epilepsy type:
- Structural: Abnormalities visible on neuroimaging, such as focal cortical dysplasia, stroke scars, or hippocampal sclerosis.
- Genetic: Diseases where a proven or presumed genetic mutation is directly responsible for the condition.
- Infectious: Epilepsy resulting from a known central nervous system infection like neurocysticercosis, HIV, or bacterial meningitis.
- Metabolic: Disorders caused by known metabolic defects such as porphyria or creatine deficiency syndromes.
- Immune: Conditions driven by autoimmune-mediated inflammation of the central nervous system, including anti-NMDA receptor encephalitis.
- Unknown: Cases where the fundamental underlying cause remains undetermined despite thorough diagnostic evaluation.
Common Clinical Missteps
Implementing the 2017 guidelines often exposes recurring procedural errors in clinical documentation and diagnostic workflows.
- Skipping Levels: Assigning a Level 3 syndrome diagnosis without documenting the specific Level 1 seizure type creates ambiguity in treatment records.
- Conflating Seizure Type with Epilepsy Type: Labeling a patient with generalized epilepsy simply because they experienced a generalized tonic-clonic seizure—ignoring subtle focal onset signs—leads to improper antiseizure medication selection.
- Ignoring Etiology: Treating epilepsy strictly as an electro-clinical phenomenon while failing to investigate structural or genetic drivers limits surgical and targeted therapeutic options.
For authoritative recommendations and full documentation standards, consult the International League Against Epilepsy.
Frequently Asked Questions
Why did the ILAE update the classification system in 2017?
The 1989 and 2001 classifications struggled to incorporate rapid advancements in neuroimaging, genetics, and video-EEG monitoring. The 2017 update provides a flexible, multi-level framework that accommodates evolving diagnostic data without breaking clinical workflows.
How does the 2017 classification handle unknown etiologies?
The guidelines explicitly include 'unknown' as a valid etiological category at any point in the diagnostic process. This acknowledges that diagnostic yields vary and prevents clinicians from forcing unproven causes into patient records.
Are older diagnostic terms completely obsolete?
Many classic terms remain clinically useful, but the 2017 guidelines standardize terminology globally. For instance, terms like "partial seizures" were officially replaced by "focal seizures" to improve clarity across international research studies.
Can a patient's epilepsy classification change over time?
Yes. As diagnostic tests yield new genetic panels, high-resolution MRI scans, or clearer EEG monitoring results, a patient's classification frequently shifts from unknown etiology to structural or genetic categories, directly impacting long-term management.
